Project Grant R01AI180196

Award Date 6/7/24
Completion Date 4/30/29
Dollars Obligated $3.5M
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
La Jolla, CA 92037, USA
Similar Awards
This Project Grant award of $3,305,720.00 was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The objective is to define the impact of maternal viral infections and inflammation on immune programming within the fetal brain and lymphoid organs in a non-human primate (NHP) model. The key products and services to be delivered under this 5-year grant include: Using an ex vivo microculture model to...
This $781,718 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports the development of a novel T cell-based vaccine to prevent Dengue virus (DENV) and Zika virus (ZIKV) infection. The award aims to design a vaccine that expresses ubiquitinated and rearranged ZIKV/DENV1-4 non-structural protein 3 (NS3) to induce cytotoxic T lymphocyte (CTL) responses without causing...
This $404,479 federal project grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) will support research to develop mechanistic insights into the kinetics of Fc receptor-mediated placental antibody transfer. The goal is to optimize maternal vaccine strategies to maximize newborn immunization against serious infections. The key products and services to be delivered under this 5-year grant...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), totaling $793,102, will support research to investigate the interplay of maternal antibody and newborn vaccine responses to influenza virus infection. The goal is to effectively vaccinate young infants when maternal antibody is at high levels, such that as maternal antibody wanes, a protective anti-influenza response is...
This federal Project Grant award for $633,074 was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Sloan-Kettering Institute for Cancer Research. The grant supports research to define the mechanisms by which the placenta protects itself from harmful B cell and antibody responses, while preserving the ability to mount effective immune responses to foreign antigens during pregnancy. Key...
This U01AT012970 Cooperative Agreement award, funded by the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310), supports a $1,144,777 study to characterize the dynamic changes in the human virome and host immune response during pregnancy and postpartum. The primary awardee, The Washington University, will lead a multi-site longitudinal study enrolling 100 pregnant women to collect samples and monitor the virome and immune responses from early pregnancy...
This $664,837 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to comprehensively screen newborns for in-utero SARS-CoV-2 infection and assess associated immune responses and clinical outcomes. The primary objectives are to: 1) Identify newborns with in-utero SARS-CoV-2 infection using a multi-faceted approach involving antibody and PCR testing of cord blood, placental...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $214,742 to Texas A&M University to conduct research aimed at identifying and characterizing Toxoplasma gondii proteins that facilitate the parasite's ability to cross the placental barrier and cause congenital infections. The research team plans to use innovative methods, including an in vitro placental barrier...
This federal Project Grant award of $219,456 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research to understand how sterile inflammation at the maternal-fetal interface impacts the developing fetal immune system in a non-human primate model. The research aims to test the hypotheses that 1) injecting the clotting agent Tisseel into the maternal-fetal interface leads to placental inflammation, and 2) this...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $545,686 to The Washington University to conduct research on the role of T cells and the cytokine interleukin-9 (IL-9) at the maternal-fetal interface in preterm labor and birth. The project aims to elucidate the mechanisms by which IL-9 promotes preterm labor and birth, define the impact of maternal IL-9 on fetal...

A NOVEL STRATEGY FOR VACCINE-INDUCED PROTECTION AGAINST MATERNAL-TO-FETAL TRANSMISSION OF ZIKA VIRUS - PROJECT SUMMARY THE LONG-TERM GOAL OF THIS PROJECT IS TO DEVELOP A VACCINE THAT CONFERS ROBUST AND DURABLE PROTECTION AGAINST TRANSPLACENTAL TRANSMISSION OF ZIKA VIRUS (ZIKV). ACCOMPLISHING THIS GOAL MAY BE CHALLENGING IN THAT THE VACCINE MAY NEED TO INDUCE BOTH ANTIBODY AND T CELL RESPONSES TO CONFER HIGHLY EFFECTIVE PROTECTION AGAINST ZIKV AT THE MATERNAL-FETAL INTERFACE (MFI). STUDIES WITH PREGNANT WOMEN IN BRAZIL HAVE SUGGESTED THAT ANTIBODY RESPONSES MAY CONTRIBUTE TO PATHOGENESIS OF CONGENITAL ZIKA SYNDROME (CZS) AND NEUTRALIZING ANTIBODY RESPONSES MAY NOT CORRELATE WITH PROTECTION AGAINST CZS. RECENT HUMAN STUDIES ALSO SUGGEST THAT THE ANTI-ZIKV ANTIBODY RESPONSE MAY BE LESS DURABLE THAN T CELL RESPONSE. HOWEVER, ONGOING ZIKV VACCINE DEVELOPMENT EFFORTS ARE FOCUSED ON ELICITING MAINLY ANTIBODY RESPONSES. BASED ON OUR PUBLISHED DATA DEMONSTRATING A CRITICAL ROLE FOR CD8 T CELLS IN PROTECTING AGAINST ZIKV INFECTION IN MULTIPLE MOUSE MODELS, WE WILL TEST OUR CENTRAL HYPOTHESIS THAT A ROBUST ZIKV VACCINE-INDUCED CD8 T CELL RESPONSE IN MOTHERS IS REQUIRED TO PROVIDE STRONG AND DURABLE PROTECTION AGAINST TRANSPLACENTAL TRANSMISSION OF ZIKV. OUR REPLICON RNA VACCINE EXPRESSING ZIKV PREMEMBRANE (PRM) AND ENVELOPE (E) OR NONSTRUCTURAL PROTEIN 3 (NS3) INDUCES ROBUST PROTECTION AGAINST ZIKV INFECTION IN PREGNANT MICE BUT ONLY PARTIAL PROTECTION IN THEIR FETUSES. THEREFORE, WE WILL USE THESE REPLICON RNA VACCINES AND MOUSE MODELS TO ACHIEVE THE FOLLOWING SPECIFIC AIMS: 1) IMPROVE VACCINE-INDUCED PROTECTION AGAINST ZIKV INFECTION DURING PREGNANCY, AND IDENTIFY THE MATERNAL IMMUNE RESPONSES ASSOCIATED WITH THE MOST PROTECTIVE AND DURABLE VACCINES. 2) TEST THE ROLE OF CD8 T CELLS IN VACCINE-INDUCED PROTECTION, AND DETERMINE PRECISE FEATURES OF MFI CD8 T CELLS ELICITED BY THE MOST PROTECTIVE AND DURABLE VACCINE. WE HAVE EXPERTISE IN EXAMINING FLAVIVIRAL PATHOGENESIS AND IMMUNITY USING MOUSE MODELS. WE ALSO HAVE A LONGSTANDING COLLABORATION WITH COLLEAGUES AT OUR INSTITUTE AND UC SAN DIEGO TO INVESTIGATE VIRUS-HOST INTERACTIONS USING GENOMICS AND HISTOPATHOLOGY-INFORMED APPROACHES.

Posted 6/7/24, 12:00 AM